Approval · Notice of Compliance 34593 · 2024
NEXTSTELLIS: Notice of Compliance 34593
Issued December 20, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34593
- Date
- December 20, 2024
- Company
- Searchlight Pharma Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph as per advisement letter
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEXTSTELLIS | Not yet assigned | — |
Medicinal ingredients
- DROSPIRENONE 3 MG per TAB
- ESTETROL MONOHYDRATE 15 MG per TAB